LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Jane Street Group LLC

Jane Street Group LLC cut its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 50.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,606 shares of the medical instruments supplier's stock after selling 15,613 shares during the period. Jane Street Group LLC owned approximately 0.07% of LeMaitre Vascular worth $1,450,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. NBC Securities Inc. raised its position in shares of LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier's stock valued at $40,000 after buying an additional 183 shares during the period. USA Financial Formulas acquired a new position in shares of LeMaitre Vascular in the 3rd quarter valued at $60,000. nVerses Capital LLC grew its holdings in shares of LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier's stock worth $66,000 after purchasing an additional 200 shares during the period. GAMMA Investing LLC grew its holdings in shares of LeMaitre Vascular by 34.3% during the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier's stock worth $68,000 after purchasing an additional 188 shares during the period. Finally, Van ECK Associates Corp acquired a new stake in shares of LeMaitre Vascular during the 2nd quarter worth about $75,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have weighed in on LMAT. Barrington Research increased their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an "outperform" rating in a research note on Friday, November 1st. StockNews.com cut shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Friday, December 13th. Cantor Fitzgerald initiated coverage on LeMaitre Vascular in a research report on Tuesday, October 15th. They issued a "neutral" rating and a $96.00 target price on the stock. Finally, Oppenheimer restated an "outperform" rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $94.57.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT traded down $1.20 during mid-day trading on Friday, hitting $92.84. The company had a trading volume of 104,605 shares, compared to its average volume of 131,066. The company has a market capitalization of $2.09 billion, a PE ratio of 50.73, a price-to-earnings-growth ratio of 2.47 and a beta of 0.93. The business's 50-day simple moving average is $97.93 and its 200 day simple moving average is $90.51. LeMaitre Vascular, Inc. has a 1-year low of $52.88 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts' consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. During the same period in the previous year, the company posted $0.33 earnings per share. The business's revenue for the quarter was up 15.6% on a year-over-year basis. On average, analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date of this dividend was Thursday, November 21st. LeMaitre Vascular's dividend payout ratio is presently 34.97%.

Insiders Place Their Bets

In other news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the sale, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.